This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Reversed-phase HPLC retention time versus reference standard | Retention depends on column, gradient, and ion-pairing agent |
| Mass confirmation | Electrospray or MALDI mass spectrometry | Doubly protonated ion near m/z 377 is consistent with about 752 Da |
| Typical purity specification | 95 percent or higher by chromatographic peak area | Lower values suggest truncated or modified peptide species |
| Storage of lyophilized powder | -20 °C, desiccated, protected from light | Powder tolerates long storage better than solution |
| Storage of solution | 2-8 °C for short periods | Freeze-thaw cycling promotes aggregation and surface adsorption |
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
On 20 January 2001 the Indian Space Research Organisation (ISRO) conducted a balloon flight from Hyderabad, India to collect stratospheric dust from a height of 41 km (135,000 ft) with a view to testing for the presence of living cells. The collaborators on this project included a team of UK scientists led by Wickramasinghe. In a paper presented at a SPIE conference in San Diego in 2002 the detection of evidence for viable microorganisms from 41 km above the Earth's surface was presented. However, the experiment did not present evidence as to whether the findings are incoming microbes from space rather than microbes carried up to 41 km from the surface of the Earth. In 2005 the ISRO group carried out a second stratospheric sampling experiment from 41 km altitude and reported the isolation of three new species of bacteria including one that they named Janibacter hoylei sp.nov. in honour of Fred Hoyle. However, these facts do not prove that bacteria on Earth originated in the cosmic environment. Samplings of the stratosphere have also been carried out by Yang et al. (2005, 2009). During the experiment strains of highly radiation-resistant Deinococcus bacterium were detected at heights up to 35 km. Nevertheless, these authors have abstained from linking these discoveries to panspermia. Wickramasinghe was also involved in coordinating analyses of the red rain in Kerala in collaborations with Godfrey Louis.
===== MeSH D08.811.913.200 – aldehyde-ketone transferases (EC 2.2) ===== MeSH D08.811.913.200.324 – acetolactate synthase MeSH D08.811.913.200.650 – transaldolase MeSH D08.811.913.200.825 – transketolase
==== Germany ==== As of August 2024, 1S-LSD remains legal in Germany, primarily due to the fact that its unique silicon-containing structural alteration circumvent the legislative controls imposed by the NpSG law. The legal status of 1S-LSD in Germany is likely subject to change with future amendments to the NpSG, similarly to its previously banned sister compounds 1V-LSD and 1D-LSD. However, it is anticipated that 1S-LSD will remain legal at least until mid-2025. An update on the 21st of November 2025 added 1S-LSD to the "NpSG" made the sale illegal in Germany ("sechste Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes (NpSG)").
== Clinical significance == Tyrosine hydroxylase deficiency leads to impaired synthesis of dopamine as well as epinephrine and norepinephrine. It is represented by a progressive encephalopathy and poor prognosis. Clinical features include dystonia that is minimally or nonresponsive to levodopa, extrapyramidal symptoms, ptosis, miosis, and postural hypotension. This is a progressive and often lethal disorder, which can be improved but not cured by levodopa. Due to the low number of patients and overlapping symptoms with other disorders, early diagnosis and treatment remain challenging. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype/phenotype correlation and outcome of these diseases, their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies, a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD). Furthermore, alterations in the tyrosine hydroxylase enzyme activity may be involved in disorders such as Segawa's dystonia, Parkinson's disease and schizophrenia. Tyrosine hydroxylase is activated by phosphorylation dependent binding to 14-3-3 proteins. Since the 14-3-3 proteins also are likely to be associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, it makes an indirect link between tyrosine hydroxylase and these diseases.
=== Beyond Black Mesa === In late 2010, a trailer for a Half-Life inspired independent short film, Beyond Black Mesa, was released. Directed by Brian Curtin, it follows the character Adrian Shephard. The full short film was released online on January 21, 2011.
Sources: en.wikipedia.org
Rarely, direct damage to the hypothalamus, such as from a stroke, will cause a fever; this is sometimes called a hypothalamic fever. However, it is more common for such damage to cause abnormally low body temperatures.
=== PPM === The PPM family, which includes PP2C and pyruvate dehydrogenase phosphatase, are enzymes with Mn2+/Mg2+ metal ions that are resistant to classic inhibitors and toxins of the PPP family. Unlike most PPPs, PP2C exists in only one subunit but, like PTPs, it displays a wide variety of structural domains that confer unique functions. In addition, PP2C does not seem to be evolutionarily related to the major family of Ser/Thr PPs and has no sequence homology to ancient PPP enzymes. The current assumption is that PPMs evolved separately from PPPs but converged during evolutionary development.
Therefore, before agreeing to any surgical procedure, the plastic surgeon evaluates and considers the woman's mental health to determine if breast implants can positively affect her self-esteem and sexual functioning.
== History == Carnitine was discovered in 1905 from muscle tissue, and it's chemical structure and properties were described in 1927. Carnitine's role as a vital metabolic compound was first hypothesized in 1952, when it was found to be essential to growth in mealworms. Mealworms with low carnitine "died fat", because they could not metabolize their stored fat when starved. Various studies in the 1950s showed that carnitine was acetylated by acyl-CoA and stimulated beta oxidation, which led researchers to the conclusion that carnitine transports fatty acids for metabolism.
Sources: en.wikipedia.org
Magnetic resonance angiography (MRA) generates pictures of the arteries to evaluate them for stenosis (abnormal narrowing) or aneurysms (vessel wall dilatations, at risk of rupture). MRA is often used to evaluate the arteries of the neck and brain, the thoracic and abdominal aorta, the renal arteries, and the legs (called a "run-off"). A variety of techniques can be used to generate the pictures, such as administration of a paramagnetic contrast agent (gadolinium) or using a technique known as "flow-related enhancement" (e.g., 2D and 3D time-of-flight sequences), where most of the signal on an image is due to blood that recently moved into that plane (see also FLASH MRI). Techniques involving phase accumulation (known as phase contrast angiography) can also be used to generate flow velocity maps easily and accurately. Magnetic resonance venography (MRV) is a similar procedure that is used to image veins. In this method, the tissue is now excited inferiorly, while the signal is gathered in the plane immediately superior to the excitation plane—thus imaging the venous blood that recently moved from the excited plane.
After Zimbabwe's independence, the new government closed its missions in Pretoria and Cape Town, only maintaining a trade mission in Johannesburg, while the South African Diplomatic Mission in Salisbury was also closed.
==== MeSH D12.776.664.962.500 – ribonucleoproteins ==== MeSH D12.776.664.962.500.500 – heterogeneous-nuclear ribonucleoproteins MeSH D12.776.664.962.500.500.061 – RNA-binding protein FUS MeSH D12.776.664.962.500.500.100 – heterogeneous-nuclear ribonucleoprotein group a-b MeSH D12.776.664.962.500.500.200 – heterogeneous-nuclear ribonucleoprotein group c MeSH D12.776.664.962.500.500.300 – heterogeneous-nuclear ribonucleoprotein d MeSH D12.776.664.962.500.500.400 – heterogeneous-nuclear ribonucleoprotein group f-h MeSH D12.776.664.962.500.500.500 – heterogeneous-nuclear ribonucleoprotein k MeSH D12.776.664.962.500.500.600 – heterogeneous-nuclear ribonucleoprotein l MeSH D12.776.664.962.500.500.700 – heterogeneous-nuclear ribonucleoprotein group m MeSH D12.776.664.962.500.500.800 – heterogeneous-nuclear ribonucleoprotein u MeSH D12.776.664.962.500.500.900 – RNA-binding protein EWS MeSH D12.776.664.962.500.625 – ribonuclease p MeSH D12.776.664.962.500.750 – ribonucleoproteins, small cytoplasmic MeSH D12.776.664.962.500.750.800 – signal recognition particle MeSH D12.776.664.962.500.875 – ribonucleoproteins, small nuclear MeSH D12.776.664.962.500.875.590 – ribonucleoproteins, small nucleolar MeSH D12.776.664.962.500.875.600 – ribonucleoprotein, u1 small nuclear MeSH D12.776.664.962.500.875.605 – ribonucleoprotein, u2 small nuclear MeSH D12.776.664.962.500.875.615 – ribonucleoprotein, u4-u6 small nuclear MeSH D12.776.664.962.500.875.620 – ribonucleoprotein, u5 small nuclear MeSH D12.776.664.962.500.875.625 – ribonucleoprotein, u7 small nuclear MeSH D12.776.664.962.500.906 – RNA-induced silencing complex MeSH D12.776.664.962.500.937 – vault ribonucleoprotein particles
Sources: en.wikipedia.org
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.
Lyophilized powder is normally stored desiccated at -20 °C, protected from light and moisture. Powder kept under these conditions is generally stable for long periods. Solutions are less stable and are usually prepared immediately before use.
A purity value from one chromatographic method does not capture every possible impurity. Related peptides with similar retention behavior, counterions, and residual solvents may not appear in the same analysis. Independent testing with an orthogonal method provides stronger assurance of identity and content.
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.